Research News
View articles by month and year
-
About 25% of Women Either Don’t Start or Don’t Finish Hormonal Therapy
A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don’t start taking the medicine or stop taking it early.
-
Femara Better Than Tamoxifen for Certain Types of Breast Cancer
Femara was better than tamoxifen in treating postmenopausal women diagnosed with estrogen-receptor-positive, HER2-negative, lobular breast cancer; it was also better at treating luminal B breast cancers.
-
Experimental Medicine Seems to Help Treat Estrogen-Receptor-Positive, HER2-Negative, Advanced-Stage Breast Cancer
An early study suggests that an experimental medicine given in combination with Femara offers more benefits in treating advanced-stage, estrogen-receptor-positive, HER2-negative breast cancer than Femara alone.
-
Fareston Is Effective Against Some Advanced-Stage Cancers That Have Stopped Responding to Aromatase Inhibitors
A small study has found that Fareston is a good treatment option for postmenopausal women diagnosed with advanced-stage hormone-receptor-positive breast cancer that grew while being treated with the aromatase inhibitors Arimidex or Femara.
-
Aromatase Inhibitors Seem Less Effective in Obese Women
A small study found that while obese women diagnosed with early-stage, hormone-receptor-positive breast cancer who took Arimidex and Femara had lower estrogen levels than before they started treatment, their estrogen levels were still more than double those of women at a healthy weight.
-
Femara Offers More Benefits Than Tamoxifen After Breast Cancer Surgery
New results boost evidence that postmenopausal women get more benefits from 5 years of Femara compared to 5 years of tamoxifen after surgery for early-stage, hormone-receptor-positive breast cancer.
-
Prolia Approved by FDA to Treat Bone Loss in Women Taking Aromatase Inhibitor
The osteoporosis drug denosumab (Prolia) is now FDA-approved to treat bone loss in women taking aromatase inhibitors.
-
Is Switching Hormonal Therapies Better Than Taking Only One?
Research suggests that taking tamoxifen for 2 to 3 years and then switching to an aromatase inhibitor might be better than taking only tamoxifen or only an aromatase inhibitor for 5 years to reduce recurrence risk and improve overall survival.
-
Aromatase Inhibitors Increase Risk of Heart Problems
Women diagnosed with early-stage, hormone-receptor-positive breast cancer who got 5 years of an aromatase inhibitor seem to be more likely to have heart problems compared to women who got 5 years of tamoxifen.
-
Aromatase Inhibitor Before Surgery May Make Lumpectomy an Option
Many women diagnosed with hormone-receptor-positive, early-stage breast cancer for whom mastectomy was recommended may be candidates for lumpectomy after taking an aromatase inhibitor.
